Cancer · 1986 · 86 citations · 18 references
MedicineOncologyPediatricsChemotherapyNeuro-oncologyPediatric NeurologyDemyelinating DiseasesDemyelinating DisordersIntrathecal ChemotherapyIntrathecal Drug DeliveryPediatric LeukemiasPediatric Neuro-oncologyAcute Leukemia ChemotherapyAcute Myeloid Leukemia TherapyDrug-induced DemyelinationIntrathecal Chemotherapy AdministrationNeurologic DeficitsPediatric Intrathecal TherapyPediatric Oncology PharmacologyPediatric Oncology Trials
Two childhood acute myelogenous leukemia (AML) patients receiving intrathecal (IT) and intravenous (IV) cytosine arabinoside (Ara-C) developed progressive ascending paralysis, resulting in death in one patient. Necropsy findings on this patient included spinal cord demyelination characteristic of Ara-C neurotoxicity. An unusual aspect of these two cases was the delay between cessation of IT therapy and the onset of neurologic symptoms. These patients received relatively low total doses of IT Ara-C and standard doses of IV Ara-C. Previous studies have shown that Ara-C equilibrates readily between serum and cerebrospinal fluid; this implies that total IV and IT doses of Ara-C may be additive in relation to development of neurotoxicity. For these reasons, use of IV and IT Ara-C in childhood AML must be approached with greater caution, especially if neurologic abnormalities develop during or after therapy.
18
Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosine
D H Ho, Emil Frei · Clinical Pharmacology & Therapeutics · 1971 · 319 citations
Handbook of Clinical Neurology
J. F. Boyd · Journal of Clinical Pathology · 1979 · 259 citations